Rhythm Pharmaceuticals, Inc. (RYTM)
119.04
+2.43
(+2.08%)
USD |
NASDAQ |
Nov 18, 16:00
119.19
+0.15
(+0.13%)
After-Hours: 20:00
Rhythm Pharmaceuticals Shareholders Equity (Quarterly) : 201.54M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 201.54M |
| June 30, 2026 | 217.30M |
| March 31, 2026 | 122.91M |
| December 31, 2025 | 139.07M |
| September 30, 2025 | 148.82M |
| June 30, 2025 | -11.91M |
| March 31, 2025 | 18.95M |
| December 31, 2024 | 21.73M |
| September 30, 2024 | 11.22M |
| June 30, 2024 | 39.34M |
| March 31, 2024 | 61.58M |
| December 31, 2023 | 169.76M |
| September 30, 2023 | 197.47M |
| June 30, 2023 | 182.28M |
| March 31, 2023 | 219.76M |
| December 31, 2022 | 264.26M |
| September 30, 2022 | 281.20M |
| June 30, 2022 | 195.63M |
| March 31, 2022 | 235.77M |
| December 31, 2021 | 284.15M |
| September 30, 2021 | 322.26M |
| June 30, 2021 | 351.69M |
| March 31, 2021 | 380.95M |
| December 31, 2020 | 166.53M |
| September 30, 2020 | 196.94M |
| Date | Value |
|---|---|
| June 30, 2020 | 225.75M |
| March 31, 2020 | 253.10M |
| December 31, 2019 | 281.02M |
| September 30, 2019 | 149.12M |
| June 30, 2019 | 181.47M |
| March 31, 2019 | 220.49M |
| December 31, 2018 | 246.26M |
| September 30, 2018 | 269.64M |
| June 30, 2018 | 284.32M |
| March 31, 2018 | 133.66M |
| December 31, 2017 | 144.79M |
| September 30, 2017 | 29.09M |
| June 30, 2017 | 14.88M |
| March 31, 2017 | 21.25M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | 32.00M |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | -0.358M |
| September 30, 2014 | |
| June 30, 2014 | 8.248M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Arrowhead Pharmaceuticals, Inc. | 50.31M |
| BioMarin Pharmaceutical, Inc. | 6.256B |
| Cytokinetics, Inc. | -321.17M |
| Exelixis, Inc. | 1.834B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 443.13M |
| Total Liabilities (Quarterly) | 241.59M |
| Debt to Equity Ratio | 0.5268 |
| Current Ratio | 2.779 |
| Net Debt Paydown Yield | 0.46% |